Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge Advises Optimera Svenska
Mandate

Vinge Advises Optimera Svenska

May 14, 2008

Vinge advises Optimera Svenska AB in their purchase of Dalskogs Ångsåg & Träförädling AB, operators within the building trade line, and their subsidiary AB S.D. Danielson. Optimera Svenska AB’s holds a strong position on the relevant market in the southern parts of Sweden. By the acquisition of Dalskogs and Danielsons Optimera receives a beneficial coverage between existing units in Värmland and Gothenburg. Optimera Sverige has a turnover of approximately SEK 2,5 billion and is a part of Optimera Gruppen AS which head quarters is located in Oslo. The Optimera group, wholly owned by French Saint-Gobain, is included in Saint-Gobain Distribution Nordic.  

Vinge’s team included partner Jan Örtenholm, joined by Magnus Hedsund, Kristian Ford, Lynn Andersson and Mathias Lindquist.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024